Oncorine

Shanghai Sunway Biotech is a pioneering Chinese biopharmaceutical company specializing in the development and commercialization of oncolytic virus therapies and gene medicines. The company achieved global recognition in 2005 when its flagship product, Oncorine (H101), became the world's first approved oncolytic virus therapy, indicated for the treatment of late-stage refractory nasopharyngeal carcinoma. Sunway Biotech's robust pipeline includes several next-generation oncolytic adenoviruses, such as H102 for hepatocellular carcinoma and H103, which expresses Heat shock protein 70 to stimulate anti-tumor immune responses. Now a wholly-owned subsidiary of Shanghai Pharmaceuticals (SPH), the company operates integrated R&D and GMP-certified manufacturing facilities in Shanghai. Sunway Biotech continues to advance the field of cancer immunotherapy through strategic collaborations and a focus on innovative viral vector platforms.